SEARCH

SEARCH BY CITATION

References

  • 1
    Acharya S, Hensley ML, Montag AC, Flemming GF. Rare uterine cancers. Lancet Oncol 2005; 6: 96171.
  • 2
    Emoto M, Charnock-Jones DS, Licence DR et al. Localisation of the VEGF and angiopoietin genes in uterine carcinosarcoma. Gynecol Oncol 2004; 95: 47482.
  • 3
    Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004; 4: 42336.
  • 4
    Shaked Y, Henke E, Roodhart JM et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 2008; 14: 26373.
  • 5
    Browder T, Butterfield CE, Kraling BM et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000; 60: 187886.
  • 6
    Drevs J, Fakler J, Eisele S et al. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy. Anticancer Res 2004; 24: 175963.
  • 7
    Bocci G, Francia G, Man S, Lawler J, Kerbel RS. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci USA 2002; 100: 1291722.
  • 8
    Klement G, Huang P, Mayer B et al. Differences in the therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin Cancer Res 2002; 8: 22132.
  • 9
    O’Leary J, Shapiro RL, Ren CJ, Chuang N, Cohen HW, Potmesil M. Antiangiogenic effects of camptothecin analogues 9-amino-20(s)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model. Clin Cancer Res 1999; 5: 1817.
  • 10
    Kamiyama H, Takano S, Tsuboi K, Matsumura A. Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor-1 alpha (HIF-1α)/vascular endothelial growth factor (VEGF) expression of glioma and growth factor of endothelial cells. J Cancer Res Clin Oncol 2005; 131: 20513.
  • 11
    Allegrini G, Falcone A, Fioravanti A et al. A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. Br J Cancer 2008; 98: 131219.
  • 12
    Takano S, Kamiyama H, Mashiko R, Osuka S, Ishikawa E, Matsumura A. Metronomic treatment of malignant glioma xenografts with irinotecan (CPT-11) inhibits angiogenesis and tumor growth. J Neurooncol 2010; 99: 17785.
  • 13
    Longo FW, Longo WE, Tomashefsky P, Lattimer JK, Rivin BD, Tannenbaum M. Interaction of ultrasound with neoplastic tissue. Local effect on subcutaneously implanted Furth-Colombia rat Wilms’ tumor. Urology 1975; 6: 6314.
  • 14
    Feril LB Jr, Kondo T, Umemura S, Tachibana K, Manalo AH, Riesz P. Sound waves and antineoplastic drugs: the possibility of an enhanced combined anticancer therapy. J Med Ultrason 2002; 29: 17387.
  • 15
    Mitragotri S. Healing sound: the use of ultrasound in drug delivery and other therapeutic applications. Nat Rev Drug Discov 2005; 4: 25560.
  • 16
    Emoto M, Tachibana K, Iwasaki H, Kawarabayashi T. Antitumor effect of TNP-470, an angiogenesis inhibitor, combined with ultrasound irradiation for human uterine sarcoma xenografts evaluated using contrast color Doppler ultrasound. Cancer Sci 2007; 98: 92935.
  • 17
    Monestiroli S, Mancuso P, Burlini A, et al. Kinetics and viability of circulating endothelial cells as a surrogate marker in an animal model of human lymphoma. Cancer Res 2001; 61: 43414.
  • 18
    Beaudry P, Force J, Naumov GN, et al. Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: Implications for use as a surrogate marker of antiangiogenic activity. Clin Cancer Res 2005; 11: 351422.
  • 19
    Emoto M, Iwasaki H, Oshima K, Kikuchi M, Kaneko Y, Kawarabayashi T. Characteristics of rhabdomyosarcoma cell lines derived from uterine carcinosarcomas. Virchows Arch 1997; 431: 24956.
  • 20
    Bocci G, Falcone A, Fioravanti A et al. Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. Br J Cancer 2008; 98: 161029.
  • 21
    Cimbaluk D, Rotmensch J, Scudiere J, Gown A, Bitterman P. Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets. Gynecol Oncol 2006; 105: 13844.
  • 22
    Nam JH, Park JY. Update on treatment of uterine sarcoma. Current opinion in obstetrics and gynecology. Curr Opin Obstet Gynecol 2010; 22: 3642.
  • 23
    Rapisarda A, Uranchimeg B, Scudiero DA et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res 2002; 62: 431624.
  • 24
    Pencreach E, Guerin E, Nicolet C et al. Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1a axis. Clin Cancer Res 2009; 15: 1297307.
  • 25
    Nowak K, Rafat N, Belle S et al. Circulating endothelial progenitor cells are increased in human lung cancer and correlate with stage of disease. Eur J Cardiothorac Surg 2010; 37: 75863.
  • 26
    Kamat AA, Kim TJ, Landen CN Jr et al. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res 2007; 67: 2818.
  • 27
    Bertolini F, Paul S, Mancuso P et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 2003; 63: 43426.
  • 28
    Barzelai S, Sharabani-Yosef O, Holbova R et al. Low-intensity ultrasound induces angiogenesis in rat hind-limb ischemia. Ultrasound Med Biol 2006; 32: 13945.
  • 29
    Rawool NM, Goldberg BB, Forsberg F, Winder AA, Hume E. Power Doppler assessment of vascular changes during fracture treatment with low-intensity ultrasound. J Ultrasound Med 2003; 22: 14553.
  • 30
    Ramli R, Reher P, Harris M, Meghji S. The effect of ultrasound on angiogenesis: an in vivo study using the chick chorioallontoic membrane. Int J Oral Maxillofac Implants 2009; 24: 5916.